Bernadette Connaughton
Director/Board Member bei HALOZYME THERAPEUTICS, INC.
Vermögen: 2 Mio $ am 31.03.2024
Profil
Bernadette Mary Connaughton is an Independent Director and Trustee.
She currently holds positions at Halozyme Therapeutics, Inc., Zealand Pharma A, Editas Medicine, Inc., and Boys & Girls Clubs of New Jersey.
She previously worked as a Director at Visterra, Inc., Head-European Markets, Canada & Australia at Bristol Myers Squibb Co., and President-China, Latin America & Middle East at Bristol-Myers Squibb Pharma Co. She also served as an Independent Director at Syneos Health, Inc. She received her undergraduate degree from The Johns Hopkins University and her MBA from The Wharton School of the University of Pennsylvania.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 26.02.2024 | 26 015 ( 0,02% ) | 1 Mio $ | 31.03.2024 | |
ZEALAND PHARMA A/S
0,01% | 31.12.2023 | 8 500 ( 0,01% ) | 840 357 $ | 31.03.2024 |
EDITAS MEDICINE, INC.
-.--% | 04.04.2023 | 0 ( -.--% ) | - $ | 31.03.2024 |
Aktive Positionen von Bernadette Connaughton
| Unternehmen | Position | Beginn |
|---|---|---|
| HALOZYME THERAPEUTICS, INC. | Director/Board Member | 10.09.2018 |
| ZEALAND PHARMA A/S | Director/Board Member | 04.04.2019 |
| EDITAS MEDICINE, INC. | Director/Board Member | 26.10.2021 |
| Boys & Girls Clubs of New Jersey | Director/Board Member | - |
Ehemalige bekannte Positionen von Bernadette Connaughton
| Unternehmen | Position | Ende |
|---|---|---|
| SYNEOS HEALTH, INC. | Director/Board Member | 28.09.2023 |
| VISTERRA INC | Director/Board Member | 01.08.2018 |
| Bristol-Myers Squibb Pharma Co. | Corporate Officer/Principal | 01.10.2017 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01.01.2017 |
Ausbildung von Bernadette Connaughton
| The Johns Hopkins University | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| HALOZYME THERAPEUTICS, INC. | Health Technology |
| ZEALAND PHARMA A/S | Health Technology |
| EDITAS MEDICINE, INC. | Health Technology |
| Private Unternehmen | 4 |
|---|---|
Visterra, Inc.
 Visterra, Inc. Pharmaceuticals: MajorHealth Technology Visterra, Inc. Is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of antibody-based therapies for kidney diseases, and other chronic diseases. It focuses on its research technology platform, HIEROTOPE technology. The company was founded by Alan L. Crane, Kevin J. Bitterman and Ram Sasisekharan on December 20, 2007 and is headquartered in Waltham, MA. | Health Technology |
| Bristol-Myers Squibb Pharma Co. | |
| Boys & Girls Clubs of New Jersey | |
Syneos Health, Inc.
 Syneos Health, Inc. BiotechnologyHealth Technology Syneos Health, Inc. engages in the provision of biopharmaceutical solutions. It operates through the Clinical Solutions and Commercial Solutions segments. The Clinical Solutions segment offers global services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics that span Phase I to IV of clinical development. It also offers individual services including regulatory consulting, project management, protocol development, investigational site recruitment, clinical monitoring, technology-enabled patient recruitment and engagement, clinical home health services, clinical trial diversity, biometrics, and regulatory affairs. The Commercial Solutions segment provides commercialization services, including deployment solutions, communications solutions, and consultancy services. The company was founded in 1998 and is headquartered in Morrisville, NC. | Health Technology |
